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Effect of Interferon-b1b on Magnetic
Resonance Imaging Outcomes in Secondary
Progressive Multiple Sclerosis: Results of a
European Multicenter, Randomized, Double-
Blind, Placebo-Controlled Trial
D. H. Miller, FRCP,* P. D. Molyneux, MD,* G. J. Barker, PhD,* D. G. MacManus, MSc,*
I. F. Moseley, FRCR,* K. Wagner, MD,† and the European Study Group on Interferon-b1b in
Secondary Progressive Multiple Sclerosis‡
A randomized placebo-controlled trial of interferon-b1b was performed on 718 patients with secondary progressive
multiple sclerosis with follow-up of up to 3 years. In addition to clinical variables, serial magnetic resonance imaging
(MRI) studies were performed to determine the effect of treatment on the pathological evolution of the disease. All
patients eligible for MRI had annual proton density/T2-weighted brain scans from which total lesion volume was mea-
sured and the number of new and enlarging lesions noted. A subgroup of 125 patients also underwent monthly
gadolinium-enhanced and proton density/T2-weighted brain MRI from months 0 to 6 and 18 to 24 to determine the
effect of treatment on the frequency of new lesion activity, defined as new enhancing lesions and new/enlarging T2
lesions not enhancing with gadolinium. The difference in total lesion volume between treatment groups was highly
significant. In the placebo group, there was an increase of 15% from baseline to last scan, whereas in the interferon-b1b
group, a reduction of 2% was seen. Within the placebo group, there was a significant year-on-year increase in total lesion
volume, with a mean increase of 16% at year 3 compared with baseline. In the treated group, there was a significant
reduction at year 1 (4%) and year 2 (5%) compared with baseline; the 2% decrease at year 3 was not significant. The
number of new or enlarging proton density/T2 lesions was also significantly reduced by treatment. In the frequent MRI
subgroup, treatment was associated with a significant 65% reduction in new lesion activity between months 1 and 6, and
78% reduction from months 19 to 24. Interferon-b1b has a substantial and sustained effect on reducing the accumu-
lation of new inflammatory disease foci in secondary progressive MS. This therapeutic mechanism may contribute to the
positive clinical benefits of treatment on the progression of sustained neurological disability and relapse activity that were
also identified in this trial.
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Recent randomized placebo-controlled trials have con-
vincingly demonstrated a favorable effect of interferon-b
(IFN-b) on clinical and magnetic resonance imaging
(MRI) outcomes in ambulant patients with relapsing–
remitting multiple sclerosis (RRMS).1–6 Reductions in
the relapse rate of about one-third have been consis-
tently reported,1,2,6 along with, in most4–6 but not
all2,3 instances, an impressive reduction in MRI activity
and change in brain total lesion volume (TLV). A trial
of IFN-b1b in RRMS reported a median reduction of
new lesions on T2-weighted imaging of about 80%,
and whereas total T2 lesion load increased by about
5% to 10% per annum in the placebo group, there was
no net change in lesion load in the treated group dur-
ing a 4-year period.4,5 The effect of IFN-b1b on
monthly gadolinium enhancing lesions has not yet
been evaluated in a placebo-controlled trial, although a
study of a small cohort of relapsing–remitting patients,
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using a baseline crossover design, suggested that there
might be a treatment-associated reduction in the num-
ber of enhancing lesions of about 80%.7
To date, there have been no published studies re-
garding the effect of IFN-b on MRI outcomes in pa-
tients with secondary progressive MS (SPMS). A
recently completed European multicenter, placebo-
controlled trial has reported clinical benefits in this pa-
tient subgroup, with a significant slowing in the sus-
tained progression of disability being the main clinical
result.8 The present report concerns the MRI outcomes
of this large trial.
Patients and Methods
Seven hundred eighteen patients with SPMS were recruited
from 32 European centers into a randomized, double-blind,
placebo-controlled trial of IFN-b1b planned for 3 years. The
trial design and inclusion and exclusion criteria of the pa-
tients have been fully described elsewhere.8,9 The study was
performed according to ICH Harmonised Guidelines:
Guidelines for Good Clinical Practice, and all patients pro-
vided informed written consent before treatment. SPMS was
defined as having had a previous relapsing–remitting course,
but subsequently entering a phase of gradual clinical progres-
sion, with or without superimposed relapses, for at least 6
months. Entry Expanded Disability Status Scale (EDSS)
score was 3.0 to 6.5, inclusive, and patients were required to
have had either two relapses or a 1-point increase in the
EDSS during the 2 years before entering the study. All pa-
tients were randomized to treatment with either placebo or
IFN-b1b (Betaseron), 8 million IU, subcutaneously on alter-
nate days. The primary outcome was time to a 1-point in-
crease in the EDSS (or a 0.5 increase if the baseline EDSS
was 6 or 6.5) confirmed at two consecutive assessments at
least 3 months apart. All the MRI studies performed at the
individual centers were transferred to the MRI Analysis Cen-
tre (Institute of Neurology, University College London,
Queen Square, London, UK), where analyses were performed
by staff who were totally blinded to the clinical details.
MRI Acquisition Protocol
Two types of MRI assessment were planned to evaluate dif-
ferent aspects of the pathology and its modification by treat-
ment. Protocols were developed accordingly.
LESION EXTENT OR CHANGES IN BRAIN TLV. To evaluate
this outcome, yearly proton density (PD) and T2-weighted
conventional spin echo (SE) scans were acquired in all pa-
tients. The parameters were as follows: repetition time
(TR) 5 2 to 2.5 seconds; short echo time (TE) 5 30 to 40
msec; long TE 5 80 to 100 msec; 28 axial oblique, contig-
uous, interleaved, 5-mm-thick slices; matrix 5 256 3 256;
field of view 5 25 cm; one or two excitations. The electronic
data from each site were used to quantify TLV. Reposition-
ing was achieved by using a protocol based on identification
of standardized anatomical landmarks.10
LESION ACTIVITY. A subgroup of 125 patients from seven
centers also underwent monthly gadolinium-DTPA (Gd)-
enhanced T1-weighted SE (TR 5 500–700 msec; TE 5
5–25 msec; 256 3 256 matrix; slice thickness 5 5 mm; 28
axial oblique, contiguous, interleaved slices) and PD/T2-
weighted SE or fast SE imaging from months 0 to 6 and 18
to 24. Acquisition of the T1-weighted scan was begun 5 to 7
minutes after the Gd injection. The dose of Gd was 0.1
mmol/kg, although one site inadvertently used 0.05
mmol/kg for the first 6 months. The analyses were therefore
performed with and without this site included (no differ-
ences in outcome were seen). At month 0, a T1-weighted SE
sequence was also obtained before the administration of Gd.
Hard copies of the annual scans in all 718 patients were also
analyzed to count the number of new and enlarging lesions.
For both types of MRI assessments, images were not ob-
tained within 1 week of corticosteroid use, to avoid bias be-
tween treatment groups.
MRI Analysis
TLV. All MRI scans at each site were archived onto hard
copy film and electronic media and transported to the MRI
analysis site. The hard copy was analyzed by a group of ex-
perienced clinical raters, working in pairs, who marked and
roughly outlined on an overlaid transparency every lesion vis-
ible on the PD-weighted scan. First, lesions were identified
and marked on the baseline scan. The month 12 study was
then compared side by side with the baseline scan, and le-
sions were marked on the month 12 study. In parallel with
this process, all new and enlarging lesions that had developed
between these time points were identified and marked by
consensus. This same approach was used to assess the month
24 against month 12 studies, and the month 36 against
month 24 studies. Finally, a review of the entire scan series
was performed to ensure a high standard of consistency in
lesion delineation across the whole scan data set. This ap-
proach, therefore, identified all the lesions to be included in
the TLV quantification and also documented the number of
new and enlarging lesions seen on each annual follow-up scan.
The electronic data were received from the scanning sites
on their usual archive media, and in their particular scanner’s
data format. They were first transferred to a “JukeBox” sys-
tem, attached to a network of Sun Workstations (Sun Mi-
crosystems, Palo Alto, CA), and then converted to a single
common format understood by all the subsequent display
and analysis tools. The data were sorted by site, patient ID
and scan date, and duplicate images (from scans repeated re-
sulting from artifacts or patient motion, or because of mul-
tiple archiving, or other problems) were discarded. Through-
out both the data conversion and sorting, the original hard
copy (received from the site immediately after a scan was
completed) was used to ensure that both the image data
themselves, and the associated patient data (eg, initials, date
of birth, and scan date) were correctly maintained.
A group of raters, previously trained to ensure a high level
of reproducibility (see below), performed the TLV analysis as
follows: (1) The hard copy with all lesions outlined was
placed alongside the identical computer-generated image. (2)
All lesions marked on the hard copy were outlined on the
computer image, using the semiautomated local thresholding
contour technique,11–13 or, if the lesion could not be out-
lined satisfactorily with this approach, manual outlining was
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performed. (3) After all lesions had been outlined, another
observer checked the consistency of lesion identification from
hard copy to computer image, and any lesions missed in the
latter were outlined by the original rater. (4) A computer
program then summed all the individual lesion volumes (cal-
culated as the surface area of each lesion multiplied by the
slice thickness [5 mm in all cases]) and a final TLV was
generated and stored in a specially constructed database.
Before starting to analyze the computerized images from
the trial patients, each rater underwent a period of compre-
hensive training in the use of the quantitative technique.
Once a rater had developed a sufficient level of expertise in
application of the technique, performance was evaluated by
using a standardized MR data set, comprising the PD-
weighted brain images of 16 MS patients with a representa-
tive range of lesion loads.13 Each rater measured the brain
lesion load on two separate occasions, separated by an inter-
val of at least 1 week. The minimum acceptance criteria for
passing this validation procedure was considered to be a me-
dian intrarater coefficient of variation of less than 5%. Only
once this had been demonstrated was a rater allowed to start
work on the trial data set.
LESION ACTIVITY. In the subgroup of those who also had
monthly scans from months 0 to 6 and 18 to 24, all hard
copy images were analyzed for lesion activity changes by two
experienced observers working by consensus. The following
outcomes were studied:
(1) The number of newly active lesions during months 1 to 6
(secondary efficacy end point of this study) and 19 to 24. A
newly active lesion was defined as an area of new Gd en-
hancement or as a new or newly enlarging PD/T2 lesion that
did not enhance.
(2) The number of persistently active lesions during months 1 to
6 and 19 to 24. These are lesions that had been newly en-
hancing on a previous scan, but continued to enhance on
follow-up studies, or (very rarely) that continued to enlarge
without enhancement, having been newly active on a previ-
ous scan.
(3) The number of active scans. These are scans that con-
tained one or more newly active lesions, during months 1 to
6 and 19 to 24.
(4) The number of active patients. These are patients who
had one or more newly active lesions, during months 1 to 6
and 19 to 24.
For the core annual protocol (all patients), the annual PD/
T2-weighted scans were analyzed by experienced raters,
working by consensus in pairs (see above), to determine the
following: (1) the number of active (ie, new or enlarging) le-
sions; (2) the number of active scans (ie, that contained one or
more active lesions); and (3) the number of active patients (ie,
who displayed one or more active lesions at some stage dur-
ing follow-up).
Statistical Analysis
The percentage change in TLV at end point (last scan avail-
able) and the number of newly active lesions during months
1 to 6 were secondary end points for this study; all other
MRI end points were considered to be tertiary. Statistical
analyses were based on the intention-to-treat population, in-
cluding all data of all patients as randomized without any
restrictive criteria. Data up to final termination of the study
were evaluated (including data collected after the time of cut-
off for the interim analysis, which lead to early termination
of the study). At the time of interim cutoff, all patients had
completed at least 24 months. Thus, the data set for the
subgroup of patients who underwent monthly scans in
months 1 to 6 and 19 to 24 was complete at month 24.
The initial rationale for sample size for the frequent MRI
subgroup was based on the work of Nauta and colleagues.14
Their results indicated that with a 6-monthly Gd-enhanced
T1-weighted imaging, a sample size of approximately 54 pa-
tients per group would allow the detection of a 60% reduc-
tion in the total number of newly active lesions. Additional
calculations were performed by Petkau,15 based on substudy
results from the trial of IFN-b1b in RRMS, which concludes
that a sample size of about 60 per group should be a mini-
mal requirement.
Baseline lesion volume and baseline number of enhancing
lesions were compared between groups by using the Wil-
coxon rank sum test. Nonparametric statistical methods16,17
were used for the analysis of all MRI end points, and p val-
ues from two-sided statistical tests were provided.
CHANGE IN TLV ON ANNUAL MRI. Treatment groups
were compared for percentage and absolute changes in lesion
volume from baseline, using a nonparametric analysis of co-
variance with stratification adjustment for center and covari-
ance adjustment for baseline lesion volume and center. Ad-
ditional year-by-year analyses were performed post hoc. Only
patients with a valid baseline scan and at least one valid on-
study scan were included in the analyses. No correction was
made for missing values.
LESION ACTIVITY ON FREQUENT MRI. The cumulative
number of newly active lesions during months 1 to 6 and
months 19 to 24 (month 18 considered as second baseline)
were analyzed separately. Values were assigned to missing
monthly MRI lesion counts by means of linear interpolation
and extrapolation from available data. Patients with missing
baseline scans were not used in the analyses. The treatment
group comparison of the cumulative number of newly active
lesions was done by using a nonparametric analysis of covari-
ance with covariance adjustment for baseline number of le-
sions and stratification adjustment for center.
The above-specified statistical methods for the treatment
comparison for cumulative numbers of newly active lesions
were also applied to persistently active lesions during months
1 to 6, and months 19 to 24.
The proportion of scans that showed lesion activity and
the proportion of active patients were compared between
treatments for the two time periods separately, using the ex-
tended Mantel-Haenszel test with stratification adjustment
for center.
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Table 1. Annual MRI Analysis: Absolute and Percentage Change in TLV from Baseline
Placebo IFN-b1b pa
Baseline TLV n 344 346
Mean (SD) 28.35 (22.46) 26.62 (21.17)
Median 23.82 21.6 0.4117
Absolute change in TLV
from baseline (cm3)
Year 1 n 321 329
Mean (SD) 1.31 (4.82) 21.22 (4.19)
Median 0.30 20.77 ,0.0001
pb ,0.0001 ,0.0001
Year 2 n 302 308
Mean (SD) 2.30 (7.58) 21.53 (5.99)
Median 0.40 21.06 ,0.0001
pb ,0.0001 ,0.0001
Year 3 n 274 293
Mean (SD) 4.26 (8.97) 20.61 (7.32)
Median 1.79 20.73 ,0.0001
pb ,0.0001 0.1530
Last scan n 330 334
Mean (SD) 4.16 (8.94) 20.73 (6.99)
Median 1.70 20.74 ,0.0001
pb ,0.0001 0.0562
Percentage change in TLV
from baseline
Year 1 Mean (SD) 3.60 (14.31) 23.71 (17.12)
Median 1.64 24.94 ,0.0001
pb ,0.0001 0.0001
Year 2 Mean (SD) 7.77 (23.31) 24.77 (24.97)
Median 2.42 26.92 ,0.0001
pb ,0.0001 0.0009
Year 3 Mean (SD) 16.01 (32.68) 21.61 (25.75)
Median 10.98 25.24 ,0.0001
pb ,0.0001 0.2847
Last scanc Mean (SD) 15.37 (31.30) 22.14 (24.57)
Median 9.67 25.34
pb ,0.0001 0.1125 ,0.0001
aNonparametric analysis of covariance with stratification adjustment for center and covariance adjustment for baseline TLV and center (except
baseline comparison: Wilcoxon rank sum test).
bt test for significance of within-group change from baseline.
cSecondary efficacy end point of this study.
MRI 5 magnetic resonance imaging; TLV 5 total lesion volume; IFN-b1b 5 interferon-b1b.
Table 2. Annual MRI Analysis: Change in Absolute TLV from Previous Year (cm3)
Placebo IFN-b1b pa
Year 0–1 n 321 329
Mean (SD) 1.31 (4.82) 21.22 (4.19)
Median 0.30 20.77 ,0.0001
pb ,0.0001 ,0.0001
Year 1–2 n 306 318
Mean (SD) 1.04 (5.20) 20.23 (3.50)
Median 0.15 20.20 0.0012
pb 0.0005 0.2464
Year 2–3 n 272 296
Mean (SD) 2.32 (5.51) 0.88 (3.75)
Median 1.04 0.37 0.0002
pb ,0.0001 0.0001
In Table 2, changes were evaluated compared with previous year including all patients with available data at two successive years. Only patients
with a valid baseline scan and at least one valid on-study scan were included in the analyses. No correction for missing values was made. In
contrast, Table 1 is a display of absolute and percentage changes for each year compared with baseline where only patients with available data
at baseline and the year of interest were included.
aNonparametric analysis of covariance with stratification adjustment for center and covariance adjustment for baseline TLV and center.
bt test for significance of within-group change from previous year.
MRI 5 magnetic resonance imaging; TLV 5 total lesion volume; IFN-b1b 5 interferon-b1b.
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LESION ACTIVITY ON ANNUAL MRI. For the number of
new or enlarging lesions detected on annual MRI, treatment
groups were compared by using the extended Mantel-
Haenszel test, stratified for center. The proportion of active
scans per patient and the proportion of active patients were
also compared between treatment groups, using the extended
Mantel-Haenszel test with stratification adjustment for center.
Results
Annual MRI Analysis
The placebo and IFN-b1b groups were well matched
with respect to their baseline TLV (Table 1); median
TLV was 23.8 cm3 in the placebo and 21.6 cm3 in the
IFN-b1b group (p 5 0.41, two-sided Wilcoxon rank
sum test).
A highly significant treatment effect on the change
in TLV was demonstrated (p , 0.0001), with an in-
crease of 15% from baseline to last scan in the placebo
group, whereas in the IFN-b1b group a reduction of
2% was seen (see Table 1).
In the placebo group, there was a significant increase
in TLV at each yearly time point when compared with
baseline TLV, and also when compared with the pre-
vious year’s TLV (Table 2, see Table 1). The absolute
and percentage increases in TLV were somewhat larger
in the third than in the preceding 2 years. At year 3,
the mean and median percentage increases in TLV
compared with baseline were 16% and 11%, respec-
tively, in the placebo group (see Table 1).
In the IFN-b1b group, there was a significant de-
crease in TLV at year 1 compared with baseline, with
mean and median decrease of 4% and 5%, respectively
(see Table 1). There was no significant change in TLV
between years 1 and 2 (p 5 0.24), but there was a
significant increase in TLV during the third year (p 5
0.0001), although to a lesser degree than that seen in
the placebo group (see Table 2). The net effect of these
changes was a nonsignificant reduction in TLV of 2%
over the 3-year period.
When the placebo and IFN-b1b groups were com-
pared, there was a highly significant difference in the
TLV change, in favor of IFN-b1b at all three annual
follow-ups compared with baseline (see Table 1; Fig 1),
and also during each yearly interval, including year 2
versus year 1, and year 3 versus year 2 (see Table 2).
There was also a highly significant reduction in the
number of new or enlarging lesions in the IFN-b1b
group at all annual time points compared with base-
line, apparent even at year 1 (Table 3; Fig 2). The
mean and median reductions compared with placebo
were 57% and 70%, respectively, during the 3 years of
follow-up. In the placebo group, 70% of patients had
activity on half or more of the follow-up scans, com-
Fig 1. Annual magnetic resonance imaging (MRI) analysis.
Percentage change in total lesion volume (TLV) (mean) seen
in the study cohort during years 1 to 3. Baseline 5 MRI scan
at study entry. ***p , 0.0001, difference between treatment
groups. IFNB-1b 5 interferon-b1b.
Table 3. Annual MRI Analysis: Lesion Activity
Placebo (n 5 345) IFN-b1b (n 5 350) pa
Cumulative number of new or enlarging
lesions calculated from baseline
Year 1 Mean (SD) 3.76 (5.37) 1.48 (3.04)
Median 2.00 0 ,0.0001
Year 2 Mean (SD) 6.67 (8.42) 2.65 (5.70)
Median 4.00 1.00 ,0.0001
Year 3 Mean (SD) 8.82 (11.3) 3.77 (7.47)
Median 5.00 1.50 ,0.0001
Proportion of active patients n (%) 289 (83.8%) 225 (64.3%) ,0.0001
Proportion of active scans per patient
0 n (%) 56 (16.2%) 125 (35.7%)
,50% n (%) 51 (14.8%) 91 (26.0%)
$50% n (%) 238 (70.0%) 134 (38.3%) ,0.0001
aExtended Mantel-Haenszel test with stratification adjustment for center.
MRI 5 magnetic resonance imaging; IFN-b1b 5 interferon-b1b.
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pared with only 38% of the IFN-b1b patients (p ,
0.0001). No active lesions were seen in 16% of placebo
and 36% of IFN-b1b patients during the study period
(p , 0.0001) (see Table 3).
Monthly MRI Activity Subgroup
At baseline, enhancing lesions were seen in 29 of 61
(47%) patients randomized to placebo and 31 of 64
(48%) patients randomized to IFN-b1b. There was no
difference between the two groups in terms of the
numbers of enhancing lesions at baseline (Table 4)
(mean 2.21 in the placebo and 2.95 in the IFN-b1b
group; p 5 0.87, two-sided Wilcoxon rank sum test).
During the first 6 months of follow-up, there was a
significant reduction in the cumulative numbers of new
(65% mean decrease) and persistently (67% mean de-
crease) active lesions in the IFN-b1b versus placebo
group (see Table 4); the difference in favor of treat-
ment was apparent at every monthly time point and
was already significant at the first month of follow-up
(p 5 0.001, for newly active lesions at month 1; p ,
0.001, for persistent activity at month 1) (Figs 3 and
4). During the first 6 months of follow-up, 31% of
placebo patients and 52% of IFN-b1b patients had no
new active lesions (p 5 0.07); 51% of placebo and
16% of treated patients had new active lesions on 50%
or more of their MRI examinations during the same
MRI period (p 5 0.0008) (see Table 4).
At month 18, which served as a “second baseline”
for scans in months 19 to 24, there was a mean of 2.43
enhancing lesions in the placebo group and 1.00 in the
IFN-b1b group (p 5 0.0613). During months 19 to
24 (Table 5), there were significantly fewer new (78%
mean decrease) and persistently (88% mean decrease)
active lesions in the IFN-b1b than in the placebo
group. The difference in favor of treatment was appar-
ent at every time point and was significant from month
19 onwards; 38% of placebo and 68% of IFN-b1b pa-
tients had no new active lesions during months 19 to
24 of follow-up (p 5 0.0046); 40% of placebo and
13% of IFN-b1b patients had exhibited new active le-
sions on 50% or more of the follow-up scans during
the same period (p 5 0.0009) (see Table 5).
Discussion
This is the first placebo-controlled trial to evaluate the
effect of IFN-b on the evolving pathological process in
SPMS. It is also, by far, the largest study, to date, in
MS in which MRI analysis has been performed. It re-
veals that IFN-b1b has a substantial effect on the
pathological evolution of disease in patients with
SPMS, and that the effect was sustained for the dura-
Fig 2. Annual magnetic resonance imaging (MRI) analysis.
Cumulative number of active lesions (mean) seen in the study
cohort during years 1 to 3. Baseline 5 MRI scan at study
entry. ***p , 0.0001, difference between treatment groups.
IFNB-1b 5 interferon-b1b.
Table 4. Frequent MRI Subgroup Analyses: Lesion Activity During Months 1 to 6
Months 1–6 Placebo (n 5 61) IFN-b1b (n 5 64) p
Number of patients with enhancing
lesions at baseline
n (%) 29 (47.5%) 31 (48.4%)
Number of enhancing lesions at baseline Mean (SD) 2.21 (3.83) 2.95 (6.56) 0.8686a
Median 0 0
Number of newly active lesionsb Mean (SD) 10.24 (14.14) 3.57 (10.24) ,0.0001c
Median 5.00 0
Number of persistently active lesions Mean (SD) 3.10 (6.03) 1.02 (2.37) 0.0009c
Median 1.00 0
Proportion of active patients n (%) 42 (68.9%) 31 (48.4%) 0.0634d
Proportion of active scans per patient 0.0008d
0 n (%) 19 (31.1%) 33 (51.6%)
,50% n (%) 11 (18.0%) 21 (32.8%)
$50% n (%) 31 (50.8%) 10 (15.8%)
aWilcoxon rank sum test.
bSecondary efficacy end point of this study.
cNonparametric analysis of covariance with stratification adjustment for center and covariance adjustment for baseline lesion number.
dExtended Mantel-Haenszel test with stratification adjustment for center.
MRI 5 magnetic resonance imaging; IFN-b1b 5 interferon-b1b.
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tion of the trial (up to 3 years). The treatment effect
was readily apparent for both the total volume of brain
abnormality visible on T2-weighted images and the
numbers of new, enlarging or contrast-enhancing le-
sions that appeared during the study period. The data
strongly support the clinical evidence for efficacy dem-
onstrated in this trial,8 and the results are now dis-
cussed in more detail.
The baseline TLV was similar and generally large in
both treatment arms of the study; mean and median
TLV values were approximately twice those reported
in previous trials involving cohorts of patients with
relapsing–remitting disease. This is consistent with the
results of previous studies of untreated cohorts.18,19
In the placebo-treated group, median TLV increased
significantly year after year. The overall percentage in-
creases from baseline (1.6%, 2.4%, and 10%, at 1, 2,
and 3 years, respectively) are somewhat lower than
those reported in previous relapsing–remitting placebo
cohorts (;5–10% per annum); this largely reflects the
much higher baseline TLV in the secondary progressive
cohort, and the absolute increase in TLV is similar to
that found in early relapsing–remitting cohorts. One
might have anticipated a linear increase in TLV from
year to year, but a greater increase was seen in the third
year. Between years 2 and 3, several sites changed their
scanner, with an increase in field strength and a no-
ticeable improvement in image quality. Such changes
can have an important impact on measured TLV,20
and this may explain the year 2 to 3 result. However,
any such effect would apply equally to both treatment
arms (because of the randomization schedule treat-
ments were balanced within centers), and the differ-
ence in outcome between the treatment groups was still
clearly evident. Thus, during year 3, the median
change in TLV was 11.05 cm3 in the placebo group
and 10.37 cm3 in the IFN-b1b group (p 5 0.0002).
In the treated group, there was a significant and sub-
Fig 3. Frequent magnetic resonance imaging (MRI) subgroup
analysis. Cumulative number of newly active lesions (mean)
seen in patients of the frequent MRI subgroup. (A) Lesion
activity during months 1 to 6 (M1–M6). Baseline 5 MRI
scan at study entry. (B) Lesion activity during months 19 to
24 (M19–M24). Baseline 5 MRI scan at month 18. *p ,
0.01; **p , 0.001; ***p , 0.0001, difference between
treatment groups. IFNB-1b 5 interferon-b1b.
Fig 4. Frequent magnetic resonance imaging (MRI) sub-
group analysis. Cumulative number of persistently active le-
sions (mean) seen in patients of the frequent MRI subgroup.
(A) Lesion activity during months 1 to 6 (M1–M6). Baseline
5 MRI scan at study entry. (B) Lesion activity during months
19 to 24 (M19–M24). Baseline 5 MRI scan at month 18.
*p , 0.01; **p , 0.001; ***p , 0.0001, difference be-
tween treatment groups. IFNB-1b 5 interferon-b1b.
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stantial reduction in TLV evident at the first follow-
up. The same phenomenon has been reported in two
previous studies in RRMS.4,6 This is likely to reflect
both (1) the striking spontaneous resolution on T2-
weighted images often seen in inflammatory/edematous
lesions of recent origin even without therapeutic inter-
vention, and (2) the effect of treatment on inhibiting
new lesion development. It is also possible that IFN-
b1b treatment facilitates a more rapid and complete
resolution of preexisting active lesions by suppressing
inflammation and creating a more favorable environ-
ment for effective repair to take place. This hypothesis
is supported by the fact that enhancement persisted in
significantly fewer baseline lesions at month 1 in the
treated group, implying an effect on the duration of
enhancement as well as its frequency. In the IFN-b1b
group during the first year of follow-up, the effect of
resolution of existing inflammatory/edematous lesions
clearly outweighed the increase in TLV because of the
small number of new lesions identified despite treat-
ment. Further reduction in TLV was not seen beyond
the first annual follow-up.
The treatment effect on the annual assessment of le-
sion activity on T2-weighted images was significant
and sustained throughout the study; thus, treatment
was associated with a 57% reduction in the mean and
a 70% reduction in the median number of new or en-
larging lesions. A similar magnitude of treatment effect
was apparent in each of the 3 years of the study.
In the frequent MRI subgroup, a significant and sus-
tained reduction in the number of new and persistently
active lesions was found. In particular, there was no
reduction of efficacy in the second period of frequent
imaging. Indeed, a slight increase in treatment effect
(vs placebo) was apparent; thus, in the first period,
there was a 65% and 68% reduction in new and per-
sistently active lesions, respectively; in the second pe-
riod, the reduction was 78% for new and 88% for per-
sistently active lesions. The overall levels of activity
were about 30% lower in the second than the first pe-
riod of follow-up. This could reflect either (1) regres-
sion to the mean, a well-recognized feature of some
clinical disease activity measures (eg, relapse rate) in pa-
tients with MS recruited into treatment trials or natu-
ral history studies, or (2) patients who were particularly
active during the first phase being lost to the trial. Fur-
thermore, the results from the first month after starting
treatment suggest a significant effect on the duration of
enhancement in addition to the number of enhancing
lesions per se. Although the pathological mechanisms
underlying this effect are as yet unclear, possibilities in-
clude a more rapid repair of the blood–brain barrier on
treatment and restriction of the inflammatory process
of established lesions.
Gadolinium-enhancing lesions have been correlated
in biopsy and postmortem studies with signs of active
inflammation.21–23 This observation, together with the
moderate correlations recently reported between lesion
volume on T2-weighted images and gadolinium en-
hancement,19,24 suggests that IFN-b1b has a marked
impact on the evolution of MRI markers of disease
progression related to new inflammatory lesion forma-
tion. Such a therapeutic mechanism may underlie the
beneficial clinical effects of IFN-b1b in reducing re-
lapse rate and slowing the accumulation of disability.
The MRI outcomes do not quantify other patholog-
Table 5. Frequent MRI Subgroup Analyses: Lesion Activity During Months 19 to 24
Months 19–24 Placebo (n 5 53) IFN-b1b (n 5 56) p
Number of patients with enhancing
lesions at baseline (month 18)
n (%) 32 (57.1%) 24 (42.9%)
Number of enhancing lesions at baseline
(month 18)
Mean (SD) 2.43 (6.75) 1.00 (2.79) 0.0613a
Median 0 0
Number of newly active lesions (relative
to month 18)
Mean (SD) 7.08 (11.05) 1.55 (5.19) 0.0008b
Median 2.00 0
Number of persistently active lesions
(relative to month 18)
Mean (SD) 3.04 (6.30) 0.36 (0.52) 0.0004b
Median 0 0
Proportion of active patients n (%) 33 (62.3%) 18 (32.1%) 0.0046c
Proportion of active scans per patient 0.0009c
0 n (%) 20 (37.7%) 38 (67.9%)
,50% n (%) 12 (22.6%) 11 (19.6%)
$50% n (%) 21 (39.6%) 7 (12.5%)
aWilcoxon rank sum test.
bNonparametric analysis of covariance with stratification adjustment for center and covariance adjustment for baseline (month 18) lesion
number.
cExtended Mantel-Haenszel test with stratification adjustment for center.
MRI 5 magnetic resonance imaging; IFN-b1b 5 interferon-b1b.
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ical features found in MS lesions, in particular, demy-
elination and axonal loss, the substrates of permanent
disability. Several other MRI markers that may be
more specific to these processes (T1 low-signal lesion
volume, brain and spinal cord atrophy, and lesion
magnetization–transfer ratios) have also been acquired
in the present trial, and the effect of IFN-b1b on these
outcomes will be the subject of future reports.
In conclusion, the present study demonstrated that
IFN-b1b has a substantial and sustained effect on re-
ducing the accumulation of new inflammatory disease
foci in SPMS. This therapeutic mechanism may con-
tribute to the clinical benefits of treatment on the pro-
gression of sustained neurological disability and relapse
activity that were the main clinical effects identified in
this trial.
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